FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2991514462> ?p ?o ?g. }

• W2991514462 endingPage "2447" @default.
• W2991514462 startingPage "2437" @default.
• W2991514462 abstract "Abstract Objective A large‐scale, double‐blind trial (SP0993; NCT01243177) demonstrated that lacosamide was noninferior to controlled‐release carbamazepine (carbamazepine‐CR) in terms of efficacy, and well tolerated as first‐line monotherapy in patients (≥16 years of age) with newly diagnosed epilepsy. We report primary safety outcomes from the double‐blind extension of the noninferiority trial (SP0994; NCT01465997) and post hoc analyses of pooled long‐term safety and efficacy data from both trials. Methods Patients were randomized 1:1 to lacosamide or carbamazepine‐CR. Doses were escalated (lacosamide: 200/400/600 mg/d; carbamazepine‐CR: 400/800/1200 mg/d) based on seizure control. Eligible patients continued randomized treatment in the extension. Primary outcomes of the extension were treatment‐emergent adverse events (TEAEs), serious TEAEs, and discontinuations due to TEAEs. Post hoc analyses of data from combined trials included 12‐ and 24‐month seizure freedom and TEAEs by number of comorbid conditions. Results A total of 886 patients were treated in the initial trial and 548 in the extension; 211 of 279 patients (75.6%) on lacosamide and 180/269 (66.9%) on carbamazepine‐CR completed the extension. In the extension, 181 patients (64.9%) on lacosamide and 182 (67.7%) on carbamazepine‐CR reported TEAEs; in both groups, nasopharyngitis, headache, and dizziness were most common. Serious TEAEs were reported by 32 patients (11.5%) on lacosamide and 22 (8.2%) on carbamazepine‐CR; 12 (4.3%) and 21 (7.8%) discontinued due to TEAEs. In the combined trials (median exposure: lacosamide 630 days; carbamazepine‐CR 589 days), Kaplan‐Meier estimated proportions of patients with 12‐ and 24‐month seizure freedom from first dose were 50.8% (95% confidence interval 46.2%‐55.4%) and 47.0% (42.2%‐51.7%) on lacosamide, and 54.9% (50.3%‐59.6%) and 50.9% (46.0%‐55.7%) on carbamazepine‐CR. Incidences of drug‐related TEAEs and discontinuations due to TEAEs increased by number of comorbid conditions and were lower in patients on lacosamide. Significance Long‐term (median ~2 years) lacosamide monotherapy was efficacious and generally well tolerated in adults with newly diagnosed epilepsy. Seizure freedom rates were similar with lacosamide and carbamazepine‐CR." @default.
• W2991514462 created "2019-12-05" @default.
• W2991514462 creator A5009185180 @default.
• W2991514462 creator A5010467234 @default.
• W2991514462 creator A5012345968 @default.
• W2991514462 creator A5044873231 @default.
• W2991514462 creator A5051201622 @default.
• W2991514462 creator A5061817335 @default.
• W2991514462 creator A5061862920 @default.
• W2991514462 creator A5065520393 @default.
• W2991514462 creator A5078489449 @default.
• W2991514462 creator A5085356343 @default.
• W2991514462 date "2019-11-21" @default.
• W2991514462 modified "2023-10-05" @default.
• W2991514462 title "Long‐term safety and efficacy of lacosamide and controlled‐release carbamazepine monotherapy in patients with newly diagnosed epilepsy" @default.
• W2991514462 cites W1703571579 @default.
• W2991514462 cites W1857985470 @default.
• W2991514462 cites W1866138264 @default.
• W2991514462 cites W1963797124 @default.
• W2991514462 cites W1970608368 @default.
• W2991514462 cites W2028500192 @default.
• W2991514462 cites W2073405024 @default.
• W2991514462 cites W2075552514 @default.
• W2991514462 cites W2084160703 @default.
• W2991514462 cites W2095094014 @default.
• W2991514462 cites W2100073316 @default.
• W2991514462 cites W2104177694 @default.
• W2991514462 cites W2148655202 @default.
• W2991514462 cites W2148849941 @default.
• W2991514462 cites W2556184649 @default.
• W2991514462 cites W2594644573 @default.
• W2991514462 cites W2791621345 @default.
• W2991514462 cites W2891964652 @default.
• W2991514462 cites W4236676256 @default.
• W2991514462 doi "https://doi.org/10.1111/epi.16381" @default.
• W2991514462 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6988520" @default.
• W2991514462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31755090" @default.
• W2991514462 hasPublicationYear "2019" @default.
• W2991514462 type Work @default.
• W2991514462 sameAs 2991514462 @default.
• W2991514462 citedByCount "13" @default.
• W2991514462 countsByYear W29915144622020 @default.
• W2991514462 countsByYear W29915144622021 @default.
• W2991514462 countsByYear W29915144622022 @default.
• W2991514462 countsByYear W29915144622023 @default.
• W2991514462 crossrefType "journal-article" @default.
• W2991514462 hasAuthorship W2991514462A5009185180 @default.
• W2991514462 hasAuthorship W2991514462A5010467234 @default.
• W2991514462 hasAuthorship W2991514462A5012345968 @default.
• W2991514462 hasAuthorship W2991514462A5044873231 @default.
• W2991514462 hasAuthorship W2991514462A5051201622 @default.
• W2991514462 hasAuthorship W2991514462A5061817335 @default.
• W2991514462 hasAuthorship W2991514462A5061862920 @default.
• W2991514462 hasAuthorship W2991514462A5065520393 @default.
• W2991514462 hasAuthorship W2991514462A5078489449 @default.
• W2991514462 hasAuthorship W2991514462A5085356343 @default.
• W2991514462 hasBestOaLocation W29915144621 @default.
• W2991514462 hasConcept C118552586 @default.
• W2991514462 hasConcept C126322002 @default.
• W2991514462 hasConcept C168563851 @default.
• W2991514462 hasConcept C197934379 @default.
• W2991514462 hasConcept C2778139780 @default.
• W2991514462 hasConcept C2778186239 @default.
• W2991514462 hasConcept C2779253243 @default.
• W2991514462 hasConcept C42219234 @default.
• W2991514462 hasConcept C67761136 @default.
• W2991514462 hasConcept C71924100 @default.
• W2991514462 hasConceptScore W2991514462C118552586 @default.
• W2991514462 hasConceptScore W2991514462C126322002 @default.
• W2991514462 hasConceptScore W2991514462C168563851 @default.
• W2991514462 hasConceptScore W2991514462C197934379 @default.
• W2991514462 hasConceptScore W2991514462C2778139780 @default.
• W2991514462 hasConceptScore W2991514462C2778186239 @default.
• W2991514462 hasConceptScore W2991514462C2779253243 @default.
• W2991514462 hasConceptScore W2991514462C42219234 @default.
• W2991514462 hasConceptScore W2991514462C67761136 @default.
• W2991514462 hasConceptScore W2991514462C71924100 @default.
• W2991514462 hasIssue "12" @default.
• W2991514462 hasLocation W29915144621 @default.
• W2991514462 hasLocation W29915144622 @default.
• W2991514462 hasLocation W29915144623 @default.
• W2991514462 hasOpenAccess W2991514462 @default.
• W2991514462 hasPrimaryLocation W29915144621 @default.
• W2991514462 hasRelatedWork W1658899326 @default.
• W2991514462 hasRelatedWork W1999498747 @default.
• W2991514462 hasRelatedWork W2032375911 @default.
• W2991514462 hasRelatedWork W2887557968 @default.
• W2991514462 hasRelatedWork W2981112956 @default.
• W2991514462 hasRelatedWork W2991514462 @default.
• W2991514462 hasRelatedWork W3008785252 @default.
• W2991514462 hasRelatedWork W3154371553 @default.
• W2991514462 hasRelatedWork W4386629393 @default.
• W2991514462 hasRelatedWork W3091894912 @default.
• W2991514462 hasVolume "60" @default.
• W2991514462 isParatext "false" @default.
• W2991514462 isRetracted "false" @default.
• W2991514462 magId "2991514462" @default.
• W2991514462 workType "article" @default.